Full Year Net Loss: $63.7 million, compared to $65.8 million in prior year. Aadi Bioscience Inc (NASDAQ:AADI) has successfully transitioned into Whitehawk Therapeutics, focusing on advanced ADC ...

Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to ...